Allergan to acquire Repros

Allergan plc (NYSE:AGN) is acquiring Repros Therapeutics Inc. (NASDAQ:RPRX) for $0.67 per share in cash. Repros said it expects the deal to close in 1Q18.

An Allergan spokesperson told BioCentury the deal adds to its genitourinary pipeline and expands its IP portfolio for ulipristal acetate (Esmya - EU, Fibristal - Canada, Ella, ellaOne, PGL4001). The selective progesterone receptor modulator (SPRM) under FDA review to treat abnormal uterine bleeding in women with uterine fibroids. Repros' pipeline includes SPRM Proellex telapristone acetate to treat symptoms associated with uterine fibroids and endometriosis, and enclomiphene citrate to treat secondary hypogonadism. ...